These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28769592)

  • 1. Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma.
    Walayat S; Hussain N; Patel J; Hussain F; Patel P; Dhillon S; Aulakh B; Chittivelu S
    Int Med Case Rep J; 2017; 10():243-246. PubMed ID: 28769592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
    Cheng PC; Alexiou S; Rubenstein RC
    Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
    Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
    Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Clinically Efficient Is Lumacaftor/Ivacaftor for Cystic Fibrosis Patients? An Updated Literature Review.
    Perveen S; Chaudhry MR; AlBabtain S; Amreen S; Brar SK; Zeb M; Khan S
    Cureus; 2020 Dec; 12(12):e12251. PubMed ID: 33520477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
    Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
    J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.